vs
Avantor, Inc.（AVTR）与EyePoint, Inc.（EYPT）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是EyePoint, Inc.的2687.6倍（$1.7B vs $619.0K）。Avantor, Inc.净利率更高（3.1% vs -10922.3%，领先10925.4%）。Avantor, Inc.同比增速更快（-1.4% vs -94.7%）。Avantor, Inc.自由现金流更多（$117.2M vs $-66.0M）。过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -77.0%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
AVTR vs EYPT — 直观对比
营收规模更大
AVTR
是对方的2687.6倍
$619.0K
营收增速更快
AVTR
高出93.3%
-94.7%
净利率更高
AVTR
高出10925.4%
-10922.3%
自由现金流更多
AVTR
多$183.2M
$-66.0M
两年增速更快
AVTR
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $619.0K |
| 净利润 | $52.4M | $-67.6M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 7.6% | -11364.3% |
| 净利率 | 3.1% | -10922.3% |
| 营收同比 | -1.4% | -94.7% |
| 净利润同比 | -89.5% | -63.3% |
| 每股收益（稀释后） | $0.08 | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTREYPT
| Q4 25 | $1.7B | $619.0K | ||
| Q3 25 | $1.6B | $966.0K | ||
| Q2 25 | $1.7B | $5.3M | ||
| Q1 25 | $1.6B | $24.5M | ||
| Q4 24 | $1.7B | $11.6M | ||
| Q3 24 | $1.7B | $10.5M | ||
| Q2 24 | $1.7B | $9.5M | ||
| Q1 24 | $1.7B | $11.7M |
净利润AVTREYPT
| Q4 25 | $52.4M | $-67.6M | ||
| Q3 25 | $-711.8M | $-59.7M | ||
| Q2 25 | $64.7M | $-59.4M | ||
| Q1 25 | $64.5M | $-45.2M | ||
| Q4 24 | $500.4M | $-41.4M | ||
| Q3 24 | $57.8M | $-29.4M | ||
| Q2 24 | $92.9M | $-30.8M | ||
| Q1 24 | $60.4M | $-29.3M |
毛利率AVTREYPT
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | 93.0% | ||
| Q2 24 | 34.1% | 85.2% | ||
| Q1 24 | 34.0% | 93.5% |
营业利润率AVTREYPT
| Q4 25 | 7.6% | -11364.3% | ||
| Q3 25 | -40.0% | -6420.8% | ||
| Q2 25 | 7.7% | -1166.8% | ||
| Q1 25 | 9.3% | -199.7% | ||
| Q4 24 | 37.8% | -390.4% | ||
| Q3 24 | 7.3% | -311.2% | ||
| Q2 24 | 10.3% | -364.5% | ||
| Q1 24 | 8.7% | -285.2% |
净利率AVTREYPT
| Q4 25 | 3.1% | -10922.3% | ||
| Q3 25 | -43.8% | -6183.4% | ||
| Q2 25 | 3.8% | -1114.3% | ||
| Q1 25 | 4.1% | -184.8% | ||
| Q4 24 | 29.7% | -357.3% | ||
| Q3 24 | 3.4% | -279.0% | ||
| Q2 24 | 5.5% | -325.3% | ||
| Q1 24 | 3.6% | -250.6% |
每股收益（稀释后）AVTREYPT
| Q4 25 | $0.08 | $-0.82 | ||
| Q3 25 | $-1.04 | $-0.85 | ||
| Q2 25 | $0.09 | $-0.85 | ||
| Q1 25 | $0.09 | $-0.65 | ||
| Q4 24 | $0.73 | $-0.65 | ||
| Q3 24 | $0.08 | $-0.54 | ||
| Q2 24 | $0.14 | $-0.58 | ||
| Q1 24 | $0.09 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $306.1M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $306.1M |
| 总资产 | $11.8B | $364.0M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTREYPT
| Q4 25 | $365.4M | $306.1M | ||
| Q3 25 | $251.9M | $204.0M | ||
| Q2 25 | $449.4M | $255.7M | ||
| Q1 25 | $315.7M | $318.2M | ||
| Q4 24 | $261.9M | $370.9M | ||
| Q3 24 | $285.3M | $253.8M | ||
| Q2 24 | $272.6M | $280.2M | ||
| Q1 24 | $234.9M | $299.3M |
总债务AVTREYPT
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTREYPT
| Q4 25 | $5.6B | $306.1M | ||
| Q3 25 | $5.6B | $200.2M | ||
| Q2 25 | $6.3B | $246.0M | ||
| Q1 25 | $6.1B | $298.4M | ||
| Q4 24 | $6.0B | $336.5M | ||
| Q3 24 | $5.6B | $218.7M | ||
| Q2 24 | $5.4B | $228.3M | ||
| Q1 24 | $5.3B | $249.9M |
总资产AVTREYPT
| Q4 25 | $11.8B | $364.0M | ||
| Q3 25 | $11.7B | $251.7M | ||
| Q2 25 | $12.8B | $301.1M | ||
| Q1 25 | $12.3B | $362.6M | ||
| Q4 24 | $12.1B | $418.5M | ||
| Q3 24 | $12.8B | $300.9M | ||
| Q2 24 | $12.7B | $324.2M | ||
| Q1 24 | $12.8B | $329.2M |
负债/权益比AVTREYPT
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-65.0M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-66.0M |
| 自由现金流率自由现金流/营收 | 7.0% | -10667.7% |
| 资本支出强度资本支出/营收 | 2.1% | 159.3% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-243.4M |
8季度趋势，按日历期对齐
经营现金流AVTREYPT
| Q4 25 | $152.7M | $-65.0M | ||
| Q3 25 | $207.4M | $-59.4M | ||
| Q2 25 | $154.4M | $-62.6M | ||
| Q1 25 | $109.3M | $-53.1M | ||
| Q4 24 | $173.3M | $-35.8M | ||
| Q3 24 | $244.8M | $-39.0M | ||
| Q2 24 | $281.1M | $-20.2M | ||
| Q1 24 | $141.6M | $-31.2M |
自由现金流AVTREYPT
| Q4 25 | $117.2M | $-66.0M | ||
| Q3 25 | $171.7M | $-60.2M | ||
| Q2 25 | $124.8M | $-63.8M | ||
| Q1 25 | $81.3M | $-53.4M | ||
| Q4 24 | $145.8M | $-36.2M | ||
| Q3 24 | $204.0M | $-40.6M | ||
| Q2 24 | $235.3M | $-21.1M | ||
| Q1 24 | $106.9M | $-32.4M |
自由现金流率AVTREYPT
| Q4 25 | 7.0% | -10667.7% | ||
| Q3 25 | 10.6% | -6226.9% | ||
| Q2 25 | 7.4% | -1196.5% | ||
| Q1 25 | 5.1% | -218.4% | ||
| Q4 24 | 8.6% | -312.7% | ||
| Q3 24 | 11.9% | -385.8% | ||
| Q2 24 | 13.8% | -222.4% | ||
| Q1 24 | 6.4% | -277.0% |
资本支出强度AVTREYPT
| Q4 25 | 2.1% | 159.3% | ||
| Q3 25 | 2.2% | 82.6% | ||
| Q2 25 | 1.8% | 22.9% | ||
| Q1 25 | 1.8% | 1.1% | ||
| Q4 24 | 1.6% | 3.3% | ||
| Q3 24 | 2.4% | 15.0% | ||
| Q2 24 | 2.7% | 9.5% | ||
| Q1 24 | 2.1% | 10.2% |
现金转化率AVTREYPT
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
EYPT
暂无分部数据
